RLS Therapeutics

RLS Therapeutics - previously known as Relay Life Sciences - is a therapeutics company developing small-molecular drugs. It was established in 2016 by Jim Monsor and Marcus Henschen. The company is headquartered in Nashville, Tennessee, United States.

Previously, RLS Therapeutics licenses clinical development technology for regulatory approval or commercialization. It is interested in further developing technologies that range from medical devices and diagnostics, as well as therapeutics for human and animal health. However, most recently, RLS Therapeutics has developed a therapeutic called recycling polycarbonyl redox therapy (RPRx). It is intended to treat mitochondrial dysfunction diseases, and the drug has been successfully used for myeloencephalitis, melanoma, and paratuberculosis treatment for horses. RPRx is intended to drive mitochondrial metabolism to restore the cell mechanisms disabled by the diseases. The drug can also be used to induce apoptosis for proliferating malignant cells. The process is done automatically, and will not impact the healthy cells.